[go: up one dir, main page]

WO2009069291A1 - タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物 - Google Patents

タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物 Download PDF

Info

Publication number
WO2009069291A1
WO2009069291A1 PCT/JP2008/003480 JP2008003480W WO2009069291A1 WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1 JP 2008003480 W JP2008003480 W JP 2008003480W WO 2009069291 A1 WO2009069291 A1 WO 2009069291A1
Authority
WO
WIPO (PCT)
Prior art keywords
prophylactic
inhalation
therapeutic composition
tobacco smoke
disease caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/003480
Other languages
English (en)
French (fr)
Inventor
Satoru Furukawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2009069291A1 publication Critical patent/WO2009069291A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

タバコの煙を吸入することにより引き起こされる疾患である慢性閉塞性肺疾患（ＣＯＰＤ）の予防及び／又は治療用組成物を提供するものである。オロット酸とその誘導体であるオロチジル酸、オロチジン、及びウリジン一リン酸(ＵＭＰ)、並びにそれらの無機塩や有機塩よりなる群から選択される１又は２以上の物質を有効成分として含有する組成物を調製する。その際、グルタチオン、Ｎアセチルシステイン、コエンザイムＱ１０、αリポ酸、ビタミンＣ、ビタミンＥ、ポリフェノール、カロチノイド等の抗酸化剤をさらに含有する組成物とすることが好ましい。予防・治療用の組成物の投与方法として、経口投与や吸入投与を挙げることができる。
PCT/JP2008/003480 2007-11-26 2008-11-26 タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物 Ceased WO2009069291A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007305017A JP2011026204A (ja) 2007-11-26 2007-11-26 タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
JP2007-305017 2007-11-26

Publications (1)

Publication Number Publication Date
WO2009069291A1 true WO2009069291A1 (ja) 2009-06-04

Family

ID=40678202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003480 Ceased WO2009069291A1 (ja) 2007-11-26 2008-11-26 タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物

Country Status (2)

Country Link
JP (1) JP2011026204A (ja)
WO (1) WO2009069291A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081604A1 (ja) * 2010-12-15 2012-06-21 キリンホールディングス株式会社 オロト酸含有組成物およびその製造方法
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
WO2018207929A1 (ja) * 2017-05-12 2018-11-15 株式会社古川リサーチオフィス 動脈血中酸素飽和度の向上剤
CN115814090A (zh) * 2022-11-22 2023-03-21 广州医科大学附属第一医院 烟草引发炎症的药物新靶点
US11890315B2 (en) 2017-11-17 2024-02-06 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
US12097238B2 (en) 2022-01-04 2024-09-24 Renovion, Inc. Aqueous solution comprising a glutathione salt
US12427180B2 (en) 2016-11-17 2025-09-30 Renovion, Inc. Treatment of respiratory tract diseases and infections with ascorbic acid compositions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2556832B1 (en) * 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease
GB2524831A (en) * 2014-04-04 2015-10-07 Ermes Medical Company Ltd New pharmaceutical use
JP6811983B2 (ja) * 2016-08-18 2021-01-13 株式会社古川リサーチオフィス 網膜神経節細胞死抑制活性を有する経口用組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505553A (ja) * 1996-11-07 2001-04-24 インスパイアー ファーマシューティカルズ，インコーポレイティド ウリジン三リン酸および関連化合物で気管支炎を治療する方法
WO2002100409A1 (en) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Antiinflammatoric and antitussive compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505553A (ja) * 1996-11-07 2001-04-24 インスパイアー ファーマシューティカルズ，インコーポレイティド ウリジン三リン酸および関連化合物で気管支炎を治療する方法
WO2002100409A1 (en) * 2001-06-11 2002-12-19 Kyowa Hakko Kogyo Co., Ltd. Antiinflammatoric and antitussive compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Encyclopedic Reference of Molecular Pharmacology", 2004, SPRINGER-VERLAG, pages: 784 - 790 *
ANDERSON C.M. ET AL.: "Potential signalling roles for UTP and UDP: sources, regulation and release of uracil nucleotides", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 18, 1997, pages 387 - 392 *
LAZAROWSKI E.R. ET AL.: "Direct Demonstration of Mechanically Induced Release of Cellular UTP and Its Implication for Uridine Nucleotide Receptor Activation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 39, 1997, pages 24348 - 24354 *
PELS RIJCKEN W.R. ET AL.: "Pyrimidine metabolism and sugar nucleotide synthesis in rat liver", BIOCHEMICAL JOURNAL, vol. 266, 1990, pages 777 - 783 *
SAIAG B. ET AL.: "Lack of uptake, release and action of UTP at sympathetic perivascular nerve terminals in rabbit ear artery", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 358, 1998, pages 139 - 145 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012081604A1 (ja) * 2010-12-15 2012-06-21 キリンホールディングス株式会社 オロト酸含有組成物およびその製造方法
US11135181B2 (en) 2014-10-28 2021-10-05 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
WO2016065419A1 (en) * 2014-10-28 2016-05-06 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
AU2015337800B2 (en) * 2014-10-28 2021-05-27 Medlab Ip Pty Ltd Treatment for depression and depressive disorders
US12427180B2 (en) 2016-11-17 2025-09-30 Renovion, Inc. Treatment of respiratory tract diseases and infections with ascorbic acid compositions
US11331318B2 (en) 2017-05-12 2022-05-17 Furukawa Research Office Co., Ltd. Arterial oxygen saturation degree improver
JPWO2018207929A1 (ja) * 2017-05-12 2020-01-23 株式会社古川リサーチオフィス 動脈血中酸素飽和度の向上剤
WO2018207929A1 (ja) * 2017-05-12 2018-11-15 株式会社古川リサーチオフィス 動脈血中酸素飽和度の向上剤
US11890315B2 (en) 2017-11-17 2024-02-06 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
US12350307B2 (en) 2017-11-17 2025-07-08 Renovion, Inc. Stable ascorbic acid compositions and methods of using same
US12097238B2 (en) 2022-01-04 2024-09-24 Renovion, Inc. Aqueous solution comprising a glutathione salt
US12419932B2 (en) 2022-01-04 2025-09-23 Renovion, Inc. Aqueous solution comprising a glutathione salt
CN115814090A (zh) * 2022-11-22 2023-03-21 广州医科大学附属第一医院 烟草引发炎症的药物新靶点
CN115814090B (zh) * 2022-11-22 2024-05-24 广州医科大学附属第一医院 烟草引发炎症的药物靶点

Also Published As

Publication number Publication date
JP2011026204A (ja) 2011-02-10

Similar Documents

Publication Publication Date Title
WO2009069291A1 (ja) タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
TNSN08326A1 (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
NZ592383A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
WO2007095043A3 (en) Pharmaceutical formulations
WO2006082523A3 (en) Pharmaceutical sustained release composition of metformin
WO2007114945A3 (en) Compositions and methods for enhancing the antioxidant status of animals
SG156613A1 (en) Use of mitochondrially targeted antioxidant in the treatment of liver diseases and epithelial cancers
WO2007093365A3 (en) Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
WO2008133330A1 (ja) ４，５－エポキシモルヒナン誘導体を含有する安定な固形製剤
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
NO20074933L (no) Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2010080754A3 (en) Nanoparticle pharmaceutical formulations
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
WO2014064652A3 (en) Stable pharmaceutical composition of peginterferon alpha-2b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08854676

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP